孟鲁司特对术后慢性鼻窦炎伴鼻息肉患者无长期附加疗效
这项前瞻性随机开放标签试验纳入72例接受内镜鼻窦手术的慢性鼻窦炎伴鼻息肉患者,术后分别接受鼻内糖皮质激素单药或联合孟鲁司特治疗1年。结果显示两组在症状总分、鼻息肉评分、Lund-Mackay评分及嗅觉客观检查上均显著改善,但组间无显著差异。结论不推荐术后CRSwNP患者在INCS基础上加用孟鲁司特。
要点
- 术后INCS单药与联合孟鲁司特在1年时疗效无显著差异。
- 两组T5SS、NPS、LMK评分及嗅觉检查均较术前显著改善。
- 不推荐术后CRSwNP患者常规加用孟鲁司特。
核心结论
- 术后CRSwNP患者在INCS基础上加用孟鲁司特不应被推荐。
研究设计与样本
- 前瞻性、随机、开放标签试验,长期随访。
- 72例接受内镜鼻窦手术的CRSwNP患者随机分为两组,每组36例,分别接受INCS单药或INCS联合孟鲁司特治疗1年。
主要发现
- 治疗1年后,INCS组和INCS联合孟鲁司特组的T5SS、NPS和LMK评分均显著降低,但两组间无显著差异。
- 嗅觉丧失的改善在两组中均被观察到,组间无差异。
- 在3个月和6个月时观察到相似的结果。
关键数值与推荐
- 疗效评估采用主观总五症状评分(T5SS)和客观鼻息肉评分(NPS)、Lund-Mackay(LMK)评分及主观嗅觉检查(Barcelona Smell Test 24)。
临床怎么用
- 术后CRSwNP患者使用INCS单药即可,无需常规加用孟鲁司特。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES/HYPOTHESIS: Eosinophils and mast cells are among the key cells in inflammatory diseases like chronic rhinosinusitis (CRS) and asthma. Leukotriene antagonists have proven to be effective in the treatment of asthma, but data about their efficacy in CRS are scarce, whereas data on montelukast as an add-on treatment to intranasal corticosteroids (INCS) in a postoperative setting are completely lacking. STUDY DESIGN: Prospective, randomized, open-label trial. METHODS: In this trial with long-term follow-up, we evaluated the efficacy of montelukast as an add-on treatment to INCS in postoperative CRS with nasal polyp (CRSwNP) patients. CRSwNP patients (N = 72) undergoing endoscopic sinus surgery were randomized in two arms for the postoperative treatment. One group (N = 36) received INCS in monotherapy, whereas the other group (N = 36) received INCS in association with montelukast for 1 year. The efficacy of montelukast with INCS was evaluated by assessing both subjective (total five-symptom score [T5SS]) and objective (nasal polyp score [NPS], Lund-Mackay [LMK] score, and subjective olfactometry [Barcelona Smell Test 24]) outcome parameters and compared with the gold standard of INCS in monotherapy. RESULTS: After 1 year of surgery, T5SS, NPS, and LMK score were significantly reduced in patients treated with either INCS or INCS plus montelukast, without significant differences between the two treatment arms. Improvement of smell loss by olfactometry was also observed with no differences between arms. Similar findings were observed at 3 and 6 months. CONCLUSIONS: These results suggest that the addition of montelukast to INCS should not be recommended in the treatment of postoperative CRSwNP patients. LEVEL OF EVIDENCE: 1b Laryngoscope, 1743-1751, 2018.
引用
- Van Gerven L, Langdon C, Cordero A, et al. Lack of long-term add-on effect by montelukast in postoperative chronic rhinosinusitis patients with nasal polyps. Laryngoscope. 2017. PMID: 29114894. doi:10.1002/lary.26989
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。